8-K: Delcath Systems Reports Positive Q4 and Full Year 2024 Results Driven by HEPZATO Adoption

Delcath Systems reports strong financial results for Q4 and full year 2024, driven by the successful launch and adoption of HEPZATO KIT, with positive adjusted EBITDA in the fourth quarter.

Summary

• Delcath Systems reported fourth quarter revenue of $15.1 million and full year revenue of $37.2 million.
• HEPZATO KIT sales contributed $13.7 million in Q4 and $32.3 million for the full year, while CHEMOSAT revenue was $1.4 million in Q4 and $4.9 million for the year.
• The company achieved gross margins of 86% in the fourth quarter and 83% for the full year.
• Delcath reported a net loss of $3.4 million for the fourth quarter and $26.4 million for the full year.
• Non-GAAP adjusted EBITDA was positive $4.6 million for the fourth quarter, but a loss of $2.5 million for the full year.
• The company's cash and investment balance at year-end was $53.2 million, supported by $41.3 million generated from warrant exercises.
• Operating cash burn for the fourth quarter was $1.0 million.
• Delcath activated 4 new U.S. centers in Q4 2024 and 2 more in early 2025, bringing the total to 16 active centers with 8 additional centers accepting referrals.
• The FDA cleared an IND application for a Phase 2 clinical trial of HEPZATO in liver-dominant metastatic colorectal cancer.
• Michael Brunner, M.D., was appointed as Senior Vice President of Interventional Oncology.
• The NCCN updated its guidelines to include HEPZATO KIT as an option for patients with hepatic-dominant uveal melanoma.

Sentiment

Score: 8

Explanation: The document presents a positive outlook due to strong revenue growth, improving profitability, and a solid cash position. The successful launch of HEPZATO KIT and expansion into new treatment centers are also encouraging signs.

Positives

• Significant revenue growth driven by HEPZATO KIT adoption.
• High gross margins indicate strong pricing power and efficient cost management.
• Positive adjusted EBITDA in Q4 2024 suggests improving profitability.
• Strong cash position provides financial flexibility for future growth initiatives.
• Expansion of treatment centers increases market access for HEPZATO KIT.
• FDA clearance for Phase 2 trial expands potential applications of HEPZATO.
• NCCN guideline update supports wider adoption of HEPZATO KIT for metastatic uveal melanoma.

Negatives

• The company still reported a net loss for both the fourth quarter and the full year.
• Full year adjusted EBITDA remained negative, despite a positive Q4.
• Selling, general, and administrative expenses increased due to commercial launch activities.

Risks

• The company's ability to successfully commercialize HEPZATO KIT remains a key risk.
• Maintaining an adequate supply of critical components for HEPZATO KIT manufacturing is crucial.
• Successful FDA inspections of facilities are necessary to ensure continued production.
• Obtaining sufficient reimbursement for HEPZATO KIT is essential for market penetration.
• The company's ability to enter into purchase and sale agreements with users of HEPZATO KIT is vital for revenue generation.

Future Outlook

The company aims to advance R&D programs targeting other liver-dominant cancers, including metastatic colorectal and breast cancer, leveraging the momentum from HEPZATO's successful launch.

Management Comments

• Gerard Michel, Delcath's Chief Executive Officer, stated that the successful launch of HEPZATO drove strong financial and operational results in 2024, including positive adjusted EBITDA in the fourth quarter.
• He also noted that as HEPZATO becomes more established, they are seeing growing adoption across treatment centers and meaningful revenue growth.

Industry Context

Delcath's focus on interventional oncology and liver-directed therapies positions it within a growing market for targeted cancer treatments. The company's HEPZATO KIT competes with other therapies for metastatic uveal melanoma and other liver cancers, but its unique hepatic delivery system offers a potential advantage in terms of efficacy and reduced systemic toxicity.

Comparison to Industry Standards

• Delcath's gross margins of 83-86% are relatively high compared to typical pharmaceutical companies, suggesting a strong pricing strategy for HEPZATO KIT.
• Companies like Sirtex Medical (acquired by Varian Medical Systems) also focus on liver-directed therapies, but utilize different approaches such as radioembolization.
• The positive adjusted EBITDA in Q4 is a significant milestone, as many small-cap biotech companies struggle to achieve profitability in the early stages of commercialization.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the increased revenue and improved financial performance.
• Employees may see increased job security and potential for career advancement.
• Patients with metastatic uveal melanoma have a new treatment option with HEPZATO KIT.
• Treatment centers can offer a valuable therapy to their patients and generate revenue.
• Suppliers may see increased demand for components used in HEPZATO KIT.

Next Steps

• Advance R&D programs targeting other liver-dominant cancers, including metastatic colorectal and breast cancer.
• Continue expanding the number of active treatment centers offering HEPZATO KIT.
• Pursue Phase 2 clinical trial of HEPZATO in liver-dominant metastatic colorectal cancer.

Key Dates